From left: Simon Zhou (General Manager of Overseas Marketing, SANXING Ningbo), David Sun (CEO, Huawei Electric Power Digitalization BU), Roque D. Bacani (Chief Information Officer, Meralco), and Perry Yang (Vice President, Huawei Optical Business Product Line) launching Huawei IDS
Communication, digitalization, and AI: Emerging cornerstones of future power systems that will accelerate the intelligent evolution of distribution networks

David Sun, CEO of Huawei’s Electric Power Digitalization BU, highlighted four drivers for energy transition: green energy and diversity, resilient grids, transparent distribution, and load electrification. He called for policy changes toward dispatch-market coordination. He also emphasized that communication, digitalization, and AI are becoming core production systems, requiring stronger capabilities in digital transformation, cybersecurity, and sustainable development.

At the forum, Mr. Sun unveiled the White Paper on Communication Target Networks for the Future Power System, introducing a pioneering architecture that features an intelligent and robust main network, integrated medium-voltage and transparent low-voltage networks, high-speed secure connectivity, and space-ground integration. The paper also outlines key tech trends, from optical and wireless to carrier and satellite communications, and underscores their transformative value.

Huawei highlighted its focus on intelligence and digitalization, working with industry players to drive power transformation. Global industry leaders also shared their insights: Al’Louise van Deventer (Technology and Engineering General Manager, Eskom) on future-ready digital practices; Momar Awa Sall (Transmission Grid Director, Senelec) on private wireless networks accelerating power modernization; Deniz COSKUN (Deputy General Manager, TEİAŞ) on restructuring communication networks for grid resilience; and Andy Liu (Overseas Solutions and Marketing Director, SANXING Ningbo) on the application of Huawei IDS.

Global industry leaders and partners join to explore the future of power systems

Power distribution networks are evolving from mechanized to automated and intelligent systems, driving technological and business model innovation. Despite creating new challenges for O&M, they have unlocked further opportunities for improving grid reliability and resource allocation.

At the forum, Huawei, Meralco, and SANXING Ningbo, unveiled the IDS that delivers four core capabilities—reliable communication, edge computing, cloud-edge collaboration, and low-voltage transparency—based on a cloud-pipe-edge-pipe-device architecture. It enables an intelligent low-voltage (400 V) distribution network with controllable line loss, visualized distribution rooms, and manageable renewables, transforming fragmented digital silos into open, integrated digital systems. The three companies also announced a lighthouse showcase initiative, sharing replicable and scalable digital transformation best practices.

Advancing digital and intelligent integration for a greener, more reliable grid

Communication, digitalization, and AI are at the heart of future power systems. Huawei will deepen R&D in digital, intelligent technologies, integrating advanced intelligence into power production. Together with global partners, Huawei is committed to developing with the power industry toward greater reliability, stronger security, and a low-carbon future.

Perion’s extension into one of the fastest-growing advertising platforms represents a big leap in TAM expansion, as TikTok Ad Revenue is expected to exceed $50 billion by 2027

NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)– Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 2027¹.

Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enabling advertisers to optimize against brand-defined business outcomes rather than platform-standard KPIs.

The new Outmax for TikTok AI Model is already delivering up to 25% better performance, demonstrating Perion’s ability to drive significant efficiency gains while maintaining the scale required by global brands.

“As we officially launch our new AI Model for TikTok, we are seeing great results for our clients,” said Tal Jacobson, CEO of Perion. “The deployment of additional Outmax AI agent Models across high-growth platforms such as TikTok enables us to work with more customers across more platforms, worldwide. The strong demand we are seeing from clients expanding their investment in TikTok reinforces the strategic direction we outlined with our recently announced 2028 targets.”

About Perion Network Ltd.

Perion is an advanced technology leader redefining advertising through AI-native infrastructure, delivering real-time media execution across CTV, digital out-of-home, commerce and retail media, social and digital environments. Powered by Outmax, the company’s proprietary AI engine, Perion helps brands, agencies, and retailers optimize spend and performance, driving measurable outcomes at scale.

For more information, visit www.perion.com

Forward Looking Statements

This press release contains historical information and forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words “will,” “believe,” “expect,” “intend,” “plan,” “should,” “estimate” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of Perion with respect to future events and are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. Many factors could cause the actual results, performance or achievements of Perion to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, but not limited to, political, economic and other developments (including the current war between Israel and Hamas and other armed groups in the region), the failure to realize the anticipated benefits of companies and businesses we acquired and may acquire in the future, risks entailed in integrating the companies and businesses we acquire, including employee retention and customer acceptance, the risk that such transactions will divert management and other resources from the ongoing operations of the business or otherwise disrupt the conduct of those businesses, and general risks associated with the business of Perion including, the transformation in our strategy, intended to unify our business units under the Perion brand (Perion One), intense and frequent changes in the markets in which the businesses operate and in general economic and business conditions (including the fluctuation of our share price), loss of key customers or of other partners that are material to our business, the outcome of any pending or future proceedings against Perion, data breaches, cyber-attacks and other similar incidents, unpredictable sales cycles, competitive pressures, market acceptance of new products and of the Perion One strategy, changes in applicable laws and regulations as well as industry self-regulation, negative or unexpected tax consequences, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, whether referenced or not referenced in this press release. We urge you to consider those factors, together with the other risks and uncertainties described in our most recent Annual Report on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (SEC) on March 25, 2025, and our other reports filed with the SEC, in evaluating our forward-looking statements and other risks and uncertainties that may affect Perion and its results of operations. Perion does not assume any obligation to update these forward-looking statements.

¹ https://www.statista.com/statistics/1305708/tiktok-ad-revenue/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310678284/en/

Contacts

Contact Information:
Perion Network Ltd.

Dudi Musler, VP of Investor Relations

+972 (54) 7876785

dudim@perion.com

HOOFDDORP, Netherlands–(BUSINESS WIRE)– As the new season brings longer days and fresh beginnings, EZVIZ is turning up the excitement with a lineup of irresistible offers during the Amazon Spring Sale. Known for delivering easy-to-use smart security products, EZVIZ is giving households the perfect opportunity to refresh their home protection with technology designed for modern living.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310567932/en/

Spring into smarter home protection: EZVIZ launches standout deals for the Amazon Spring Sale

As homes open up to the energy of spring, whether welcoming guests, receiving more deliveries, or simply spending more time outdoors, this seasonal sales on Amazon offers a timely chance to upgrade everyday security. During the Spring Sale, shoppers can enjoy limited-time savings on a curated selection of EZVIZ’s smart cameras and entryway products, making it easier to safeguard front doors, gardens, and outdoor spaces while embracing the vibrant rhythm of the season.

C8c 3K Pan-Tilt Wi-Fi Camera – now £39.86, saving £10.13

Powerful outdoor protection with crystal-clear detail. With sharp 3K resolution and pan- -tilt coverage that reaches every corner, the EZVIZ C8c 3K minimizes blind spots around the home. Smart AI detection identifies people and vehicles while auto-tracking follows movement in real time, delivering accurate alerts and dependable outdoor security day and night.

EP3x Pro Video Doorbell Kit – now £75.98, saving £14.01

See more of what matters at the front door. The EZVIZ EP3x Pro features a dual-lens design, pairing a sharp 2K main lens with a downward-facing camera to monitor both visitors and packages in one view. Smart detection sends alerts for people and deliveries, while built-in 32GB local storage and solar-assisted power help keep the doorbell running smoothly without ongoing subscription fees.

C6N G1 4K Indoor Pan-Tilt Camera – now £36.09, saving £23.9

Smarter indoor monitoring with full-room visibility. The EZVIZ C6N G1 captures ultra-clear video and uses a pan-and-tilt design to provide near-360° room coverage, ensuring nothing goes unseen. Smart motion tracking automatically follows activity and sends instant alerts, while two-way talk allows users to check in and communicate from anywhere through the EZVIZ app.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310567932/en/

Contacts

Hazel Han

hanxiao16@ezviz.com

• Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur^®
• Continued ramp-up in the US for Adstiladrin^®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver
• Commitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries

SAINT-PREX, Switzerland–(BUSINESS WIRE)– Ferring today published its 2025 Annual Report and Sustainability Report. The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur^® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin^® (nadofaragene firadenovec-vncg).

Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER – with the difference being driven by the weaker US dollar.

Following a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation.

Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.”

Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%.

Access to affordable healthcare is embedded in Ferring’s purpose and strategic priorities. The Project Family: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310378948/en/

Contacts

For more information, please contact

Carine Julen
Senior Manager, Corporate Communications & Public Affairs
carine.julen@ferring.com

NUREMBERG, Germany–(BUSINESS WIRE)– Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of its range of Quectel Pi series of single-board computers (SBCs), designed for a broad range of industrial use cases. The portfolio currently includes three compact development platforms – the Quectel Pi M1, L1, and H1 boards – engineered for low power consumption, cost efficiency, and full-stack software support. Designed to accelerate prototyping and product development, they are well suited for embedded applications, IoT solutions, robotics projects, and edge computing deployments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310949640/en/

Quectel unveils versatile Pi series SBCs to power developer innovation

“We’re delighted to launch the affordable, versatile, open source Quectel Pi series of SBCs to help developers of real IoT projects in areas such as home automation, robotics, sensors and edge computing to achieve their goals,” says Zjelko Maric, Product Development Manager, EMEA, Quectel Wireless Solutions. “It is important to stress that these boards are for industrial use cases, not just the educational sector. We look forward to supporting the developer community at all levels with these highly capable new Quectel Pi boards.”

SBCs are a complete computer on a single printed circuit board (PCB) and comprise the CPU, GPU, memory storage and I/O ports. Versatility is assured thanks to Wi-Fi, Bluetooth, LTE and Ethernet connectivity options and general-purpose input/output pins to support I2C, SPI and UART interfaces. In addition to powerful CPU and GPU capabilities, support for LTE in the Quectel Pi M1 and L1 boards brings new connectivity capabilities to this sector of the market, and the Quectel H1 Pi board opens up edge computing performance for developers including industrial and commercial developers, educators and students, prosumer and home users, tech enthusiasts and developers, and hobbyists and makers.

With dimensions of 68.70mm x 108.94mm x 23.00mm, the Quectel Pi H1 is powered by the Qualcomm QCS6490 processor and offers numerous interfaces, 8GB LPDDR4x and 128GB UFS memory, an Adreno 643 GPU and options to select the Linux, Debian or Ubuntu operating systems. The SBC also supports 2.4GHZ and 5GHz Wi-Fi, Bluetooth 5.0 and gigabit ethernet connectivity.

Also included in the range is the Quectel Pi M1 and L1 boards, both offering LTE Cat 4 connectivity to users. The Pi M1 product is powered by the Qualcomm SM6115 processor and has dimensions of 56mm x 85mm x 23mm. A wide range of interfaces make this board highly compatible with the Raspberry Pi and the needs of that community of developers. This SBC also offers Wi-Fi5, Bluetooth 5.0 and gigabit ethernet as well as LTE Cat 4 and the option of GNSS connectivity. The Quectel Pi M1 also offers 4GB LPDDR4x and 64GB eMMC memory and the option of Linux, Android or Ubuntu operating systems.

The Quectel Pi L1 board features a 64-bit ARM quad-core Qualcomm QCM2290 processor alongside a rich set of interfaces, a 64-bit Adreno 702 GPU and offering 2 GB LPDDR4X* + 32 GB eMMC memory. With dimensions of 56mm x 85mm x 21.66mm, this SBC offers easy compatibility with the Raspberry Pi and offers two SIM interfaces. The Quectel Pi L1 board offers LTE Cat 4, 2.4GHz and 5GHz Wi-Fi, Bluetooth 5.0, and the option of GNSS connectivity. Both the M1 and L1 boards are designed to integrate seamlessly into existing development board ecosystems, enabling straightforward adoption and compatibility with widely used hardware platforms.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global end-to-end IoT solutions provider backed by outstanding support and services.

With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com or LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310949640/en/

Contacts

Media contact: media@quectel.com

NUREMBERG, Germany–(BUSINESS WIRE)– Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today reiterates that its cybersecurity program for its module portfolio supports compliance with the European Union’s Cyber Resilience Act (CRA), ahead of the 11 September 2026 deadline. Quectel’s best practice product security ensures customers can meet the CRA’s mandatory requirements for security by design, SBOM availability and vulnerability disclosure and incident reporting, reinforcing Quectel’s commitment to delivering secure, future-ready IoT solutions for the European and global markets.

Quectel has worked closely with Finite State, a leader in connected device and software supply chain security, to ensure Quectel’s product portfolio is both secure and compliant for the EU CRA and other industry standards globally. The partnership reinforces a clear focus on transparency, regulatory alignment and a commitment to maintaining industry-leading cybersecurity standards.

“Finite State has been Quectel’s third party cybersecurity firm for over four years, underlining our commitment to module security,” commented Willis Yang, Senior Vice President, Quectel Wireless Solutions. “Compliance and security have been a critical element in our approach to product design. Having Finite State to test and verify the security of our products is another critical part to ensure our customers are served with high quality and high security products.”

Quectel’s approach to cybersecurity and the partnership with Finite State enables Quectel customers to move forward with the confidence that their products are aligned with the requirements of the EU Cyber Resilience Act. By integrating Finite State’s security validation, Quectel IoT modules are delivered pre-tested and audit-ready, supported by comprehensive security documentation, including Software Bills of Materials (SBOMs), VEX files, and detailed vulnerability reporting.

“Our partnership with Quectel demonstrates a clear and measurable commitment to regulatory-grade cybersecurity,” said Matt Wyckhouse, CEO of Finite State. “By integrating continuous security testing throughout the product lifecycle and providing full transparency through Software Bills of Materials, Quectel has been leading the module industry in its cybersecurity approach for over four years. This disciplined, standards-based approach enables customers to meet mandatory security and reporting obligations with greater confidence and reduced risk.”

Under the CRA, manufacturers must ensure the security of their devices throughout the entire product lifecycle, including the provision of timely updates and effective vulnerability management. Compliance must also be demonstrable, supported by comprehensive technical documentation and verifiable evidence to satisfy regulatory scrutiny and market surveillance requirements.

Through its collaboration with Finite State, Quectel continues to strengthen its module security across three critical pillars: rigorous, independent security testing that goes beyond internal validation to provide externally verifiable assurance; full software supply chain visibility, delivering transparency into every software component embedded within its modules to support customer compliance and audit requirements; and comprehensive risk management, underpinned by continuous monitoring and structured remediation processes designed to keep pace with an increasingly complex regulatory environment and rapidly evolving cybersecurity threats.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global end-to-end IoT solutions provider backed by outstanding support and services.

With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com or LinkedIn.

About Finite State

Finite State is the Product Security Automation Platform for connected devices. We help manufacturers secure every release and prove compliance continuously by turning firmware, source code, and supplier inputs into a single, reviewable system for inventory, exposure prioritization, remediation workflows, and audit-ready evidence. Through a combination of automation and hands-on security services, Finite State helps organizations operationalize product security programs, scale security and compliance workflows, and deliver consistent, defensible outcomes across complex device portfolios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309391098/en/

Contacts

Media contact: media@quectel.com

• ABB Robotics integrates NVIDIA Omniverse libraries into RobotStudio^® to deliver physical AI for industry, closing the gap from virtual training to real-world deployment with up to 99% accuracy
• New RobotStudio HyperReality, available second half of 2026, will fundamentally change how quickly and reliably manufacturers can scale production, reducing costs by up to 40% and accelerating time-to-market by 50%
• Full range and breadth of industrial applications, with real-world pilot being conducted by Foxconn in consumer electronics assembly
• At NVIDIA GTC, the robotic workforce company WORKR will showcase how it’s using the solution to help manufacturers across the U.S. addressing critical labor shortages

ZURICH–(BUSINESS WIRE)– ABB Robotics announced today it is integrating NVIDIA Omniverse libraries into ABB Robotics’ RobotStudio® to help manufacturers deploy physical AI in real world robotics applications.

“Today, using NVIDIA accelerated computing and simulation technologies, we have removed the last barriers to making industrial and physical AI a reality at a global scale by closing the sim-to-real gap,” said Marc Segura, President of ABB Robotics. “For more than 50 years, ABB Robotics has led the evolution of intelligent industrial automation, from pioneering the first generation of fully electric industrial robots to advancing digital twin simulation through RobotStudio^® and shaping a new area of autonomous and versatile mobile robots. Today’s announcement with NVIDIA brings physical AI to industry at scale.”

The collaboration focuses on combining ABB Robotics’ software programming, design and simulation suite, RobotStudio, with the physically accurate simulation power of NVIDIA Omniverse libraries to close technology’s long-standing ‘sim-to-real’ gap. Developers can simulate robots in digital twins and generate synthetic data to train their physical AI models, enabling businesses of all types and sizes to deploy AI-driven robotics for various industrial workflows.

Called RobotStudio HyperReality, the resulting physically accurate simulations and foundation models are endlessly optimized with real-world data feedback continuously improving the system. These models can be used to train any number of ABB robots, anywhere in the world, with the reliability and accuracy demanded by industry.

“The industrial sector needs physically accurate simulation to bridge the gap between virtual training and the real-world deployment of AI-driven robotics at scale,” said Deepu Talla, vice president of robotics and edge AI at NVIDIA. “Integrating NVIDIA Omniverse libraries into RobotStudio brings advanced simulation and accelerated computing to ABB Robotics’ unique virtual controller technology, accelerating how manufacturers of all sizes bring complex products to market.”

Closing the ‘sim-to-real’ gap

The long-standing deficit between simulation accuracy and real-world lighting, materials and environments is known as the ‘sim-to-real’ gap. For decades, this gap has limited the ability of manufacturers to design and develop advanced manufacturing processes in the virtual world.

By integrating NVIDIA Omniverse libraries into RobotStudio, ABB Robotics will deliver unprecedented robotics simulation and synthetic data generation capabilities that will allow intelligent robots to bridge this gap with up to 99 percent accuracy. ABB is the only robot manufacturer with a virtual controller running the same firmware as the hardware, ensuring near‑perfect correlation between simulation and real‑world performance. Combined with ABB Robotics’ Absolute Accuracy technology, which reduces positioning errors from 8–15 mm to around 0.5 mm, ABB delivers unmatched precision in both virtual and physical environments, making it suited to high-precision industrial-grade applications.

This innovation enables manufacturers to design, test, and optimize production lines virtually, cutting setup and commissioning times by up to 80 percent, reducing costs by up to 40 percent by eliminating the need for physical prototypes, and accelerating time-to-market for complex products such as consumer electronics by 50 percent¹.

ABB Robotics is also assessing the potential to integrate the NVIDIA Jetson edge computing platform into its Omnicore controller to achieve real-time AI inference at the edge for its extensive robot portfolio. Today’s announcement builds upon ABB Robotics’ long-standing work with NVIDIA, including the previous integration of NVIDIA Jetson into ABB Robotics’ VSLAM autonomous mobile robots as well as the development of gigawatt-scale AI data centers.

Real-world applications, today

RobotStudio HyperReality will serve industrial clients at any scale, across a breadth of industries and applications, with select customers already testing its capabilities ahead of a full release to ABB Robotics’ 60,000 RobotStudio customers worldwide in the second half of 2026.

Foxconn, the world’s largest electronics contract manufacturer, is piloting the first joint use case in consumer electronics assembly. Automating the assembly of a tiny piece in consumer electronics is challenging, as multiple device variants require different production methods and the delicate metal structure requires precise pick-and-place and assembly control, as well as fine-tuned setup, often demanding additional debugging time and engineering resources. Using RobotStudio HyperReality, Foxconn’s assembly robots are trained virtually, using synthetic data to perfect multiple real-world production processes in various scenarios, before moving them to the production line with 99 percent accuracy. By optimizing production lines virtually, Foxconn will reduce set-up times and costs by eliminating physical training and tests, and accelerate time-to-market for consumer electronics.

“Precision is everything in consumer electronics manufacturing and until now, this level of accuracy and fidelity just wasn’t possible in simulation and digital twins,” said Dr. Zhe Shi, Chief Digital Officer of Foxconn. “We’re incredibly excited by the potential of ABB Robotics and NVIDIA’s collaboration, which enables parallel engineering for better designs, faster production ramp‑up and greater product evolution through advanced AI inference and understanding.”

WORKR, a California based robotic workforce company that delivers robotic manufacturing solutions to industry, is extending the reach of this technology to small and medium manufacturers across the United States. At NVIDIA GTC 2026 (March 16-19, San Jose, CA), WORKR will demonstrate AI- powered robotic systems built on ABB technology, trained with synthetic data using NVIDIA Omniverse libraries, and deployed without operators needing to know any programming. By combining ABB’s industrial grade robotics with its proprietary WorkrCore AI platform, the company is helping manufacturers address critical labor shortages with its robotic workforce that can learn new tasks in minutes and be operated by anyone.

“This collaboration is about making industrial AI deployable today,” said Ken Macken, CEO & Founder of WORKR. “Together with ABB and NVIDIA, we’re proving that advanced automation can work for manufacturers of any size.”

1. ABB Robotics analysis

ABB Robotics as one of the world’s leading robotics companies, is the only company with a comprehensive and integrated AI-powered portfolio covering robots, cobots and Autonomous Mobile Robots (AMRs), designed and orchestrated by our value-creating software. We help companies of all sizes and sectors – from automotive to electronics and logistics – to outperform by becoming more resilient, flexible and efficient. ABB Robotics is at the forefront of developing and commercializing a new generation of Autonomous Versatile Robotics (AVR), leading a global innovation ecosystem of partners in advancing efficient hardware and intelligent software with industrial performance. The business employs approximately 7,000 people. go.abb/robotics

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309674828/en/

Contacts

Media Relations
Rory Smith

Email: rory.smith@gb.abb.com

• Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience
• Delivers advanced antioxidant protection by day¹ and accelerated repair by night, with visible results in as little as 7 days²
• In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C³
• Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance

ZUG, Switzerland–(BUSINESS WIRE)– Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.

While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive skin in mind. Despite rapid growth, many formulations prioritize potency over skin compatibility, narrowing options for those who require both efficacy and tolerance. This gap is especially significant given that, globally, an estimated 78% of people report experiencing skin sensitivity⁴, according to research from Galderma’s Global Sensitive Skincare Faculty (GSSF). Further Galderma research demonstrates that sensitive skin exhibits 16% higher oxidative stress compared to non-sensitive skin under modern environmental conditions⁵. Together, these findings underscore the need for solutions designed to meet the needs of sensitive skin across ages, environments, and lifestyles.

Cetaphil’s AM/PM Antioxidant Serums were developed to address this unmet need, introducing a new approach that pairs advanced antioxidant science with formulations specifically engineered for sensitive skin, delivering performance without compromising barrier health.

Breakthrough antioxidant technology designed for sensitive skin

At the core of Cetaphil’s AM/PM Antioxidant Serums is a unique Gallic-AOX Power Technology, a proprietary antioxidant complex that redefines what antioxidant care can look like for sensitive skin. Combining Gallic Acid and Vitamin E, this advanced technology neutralizes free radicals more efficiently than traditional antioxidants like vitamin C, helping sensitive skin defend itself against oxidative stress without triggering irritation.

In global laboratory testing, Gallic Acid demonstrated more than twice the antioxidant efficacy of Vitamin C³, establishing a new benchmark in antioxidant performance. In global clinical evaluations, consistent use of the AM/PM system resulted in skin that is up to 7x stronger against daily stressors⁶, reinforcing the role of targeted antioxidant care in supporting barrier health for sensitive skin.

The technology builds on emerging research linking oxidative stress, lifestyle factors, and barrier disruption to periods of heightened skin sensitivity, and is further supported by new research published in collaboration with Galderma’s Global Sensitive Skincare Faculty (GSSF), reinforcing the connection between oxidative stress and sensitive skin.

Each formula was co-developed with dermatologists and clinically tested on sensitive skin to ensure both efficacy and long-term tolerability. This science-led approach reflects Cetaphil’s continued focus on aligning advanced efficacy with the unique needs of sensitive skin.

Dermatologists increasingly recognize oxidative stress as a key contributor to skin sensitivity and barrier disruption.

A new approach to antioxidant care for sensitive skin

Environmental aggressors, lifestyle stress, and overuse of active ingredients can contribute to oxidative stress, weakening the skin barrier and intensifying sensitivity. While oxidative stress affects all skin types, sensitive skin often responds with heightened inflammation, making daily antioxidant care both essential and difficult to tolerate.

Cetaphil’s AM/PM Antioxidant Serums were developed as a complementary day-and-night system, formulated to work in sync with the skin’s natural daily rhythm:

• AM Advanced Defense Serum helps defend against daily environmental stressors, including pollution, stress and blue light, while strengthening the skin barrier to leave skin visibly more resilient – powered by niacinamide and triple hyaluronic acid to help hydrate, soothe, and support skin barrier health.
• PM Repair & Renew Serum supports overnight recovery, helping to repair the skin barrier and address accumulated damage to restore the appearance of stressed, sensitive skin, delivering 2x faster skin barrier repair overnight⁷ and visibly plumper, more even-looking skin in as little as seven days⁸ – with hyaluronic acid, pro-vitamin B5, cica, and bifida ferment to help hydrate, soothe, and support skin recovery.

About Cetaphil®

Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin’s health every day. For more information, visit www.cetaphil.com.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Galderma. Data on file. SPR.3438.207553
2. Galderma. Data on file. SPR.3438.207551.
3. Galderma Data on files – Gematria reports GD-AP-01a-2023, GD-AP-03-2023 and GD-AP-04-2023​
4. Vidal SI, et al., Defining the Prevalence, Clinical Characteristics, and Demographic Influences on Patients with Sensitive Skin Syndrome: Insights from the Largest Global Survey of Sensitive Skin EADV Congress; 2025; Paris. Poster.
5. Galderma data on file, RD.SPR.3438.2017106
6. Galderma. Data on file. SPR.3438.207557
7. Galderma. Data on file. SPR.3438.207551
8. Galderma data on file SPR.3438.207557 2, SPR.3438.207558

View source version on businesswire.com: https://www.businesswire.com/news/home/20260308270674/en/

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com
+41 76 249 90 87

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com
+1 (786) 451 77 40

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX-

-These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting-

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX^® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT.

This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX when administered preoperatively and postoperatively as part of multimodal therapy, most commonly with acetaminophen and ibuprofen, in a range of reconstructive and aesthetic plastic surgeries where patients typically experience moderate-to-severe pain and are typically treated with opioid therapy for at least 72 hours postoperatively. The study dosed 99 patients who underwent aesthetic and reconstructive surgeries, including reconstructive and aesthetic breast surgeries, liposuction or abdominoplasty with liposuction, or turbinoplasties. The primary endpoint was the proportion of patients who achieved excellent, very good or good on the Patient Global Assessment scale at the end of treatment. The study showed that 90.7% of patients (95% CI: 83.1%, 95.7%) rated the effectiveness of JOURNAVX as part of multimodal treatment as excellent, very good or good. 90.9% of patients did not require any rescue opioids after surgery through the end of treatment (up to 14 days). Of the nine patients who received rescue opioids, the average use was approximately 2 tablets over 2 days.

JOURNAVX was generally safe and well tolerated with no serious adverse events related to JOURNAVX. Adverse events were mild or moderate in severity and consistent with the postoperative setting.

“As a surgeon, effective pain management is a cornerstone of patient recovery, and the data from this study highlight the potential of JOURNAVX in enabling opioid-free recovery for patients across a broad range of surgeries,” said Samuel Lin, M.D., F.A.C.S., lead author of the study; Director of Aesthetic Surgery, Beth Israel Deaconess Medical Center; Chief of Plastic Surgery, Beth Israel Deaconess Hospital—Needham; and Associate Professor of Surgery at Harvard Medical School. “By integrating JOURNAVX into a multimodal treatment approach, we are not only effectively managing pain but also potentially reducing the risks associated with opioid use, which is a critical advancement for both patients and the broader medical community.”

These data will be presented on March 6, 2026, as a poster presentation at 11:00 a.m. MT and part of the #6 Flash Talk presentation from 2:40–2:50 p.m. MT during the AAPM meeting.

If you are a health care professional and would like more information about JOURNAVX, visit www.journavxhcp.com. If you are a patient and would like more information about JOURNAVX, visit www.journavx.com.

About Journavx

JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potentials). Because JOURNAVX blocks pain signals only found in the periphery, not in the brain, JOURNAVX provides effective relief of pain without the limitations of certain currently available therapies, including the addictive potential of opioids.

The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain, including postoperative pain, on January 30, 2025.

JOURNAVX^® (suzetrigine) INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

JOURNAVX is a prescription medicine used to treat adults with moderate-to-severe short-term (acute) pain, including postoperative pain.

It is not known if JOURNAVX is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Patients should not take JOURNAVX if they take certain medicines that are strong inhibitors of an enzyme called CYP3A. Patients should ask their healthcare providers if they are not sure.

Before taking JOURNAVX, patients should tell their healthcare provider about all of their medical conditions, including if they: have liver problems, as people with liver problems may have an increased risk of getting side effects from taking JOURNAVX; are pregnant or plan to become pregnant, as JOURNAVX may temporarily reduce the chance of females becoming pregnant while on treatment; or are breastfeeding or planning to breastfeed.

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking JOURNAVX with certain other medicines may affect the way JOURNAVX and the other medicines work and may increase patients’ risk of side effects. Patients should ask their healthcare provider or pharmacist for a list of these medicines if they are not sure.

Patients should especially tell their healthcare provider if they take hormonal birth control medicine (contraceptives) containing progestins other than levonorgestrel or norethindrone as they may not work as well during treatment with JOURNAVX. Patients should also use nonhormonal contraceptives such as condoms or use other forms of hormonal birth control during treatment and for 28 days after they stop taking JOURNAVX. Medicines that are substrates of the CYP3A enzyme may become less effective during treatment with JOURNAVX. Their healthcare provider may need to adjust the dose of patients’ medicine when starting or stopping JOURNAVX.

Patients should not take food or drink containing grapefruit while taking JOURNAVX.

The most common side effects for patients treated with JOURNAVX include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Patients should tell their healthcare provider if they have any side effect that bothers them or that does not go away. These are not all of the possible side effects of JOURNAVX. Patients should call their healthcare provider for medical advice about side effects. Patients may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, for JOURNAVX.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 16 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements made by Samuel Lin, M.D., F.A.C.S., and statements regarding the clinical benefits of JOURNAVX. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, and other risks listed under the heading “Risk Factors” in Vertex’s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260305209438/en/

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com

Media:
mediainfo@vrtx.com
or

U.S.: 617-341-6992

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland–(BUSINESS WIRE)– Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.

• Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency¹ basis, primarily driven by volume.
• Broad-based net sales growth, growing double-digits in both International markets and the U.S.
• Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency.
• Strong launch momentum across future growth drivers, including Nemluvio^® (nemolizumab) delivering 452 million USD in net sales; Relfydess (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra^® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfolio of flagship brands.
• Significant progress and strategic investments across a robust innovation pipeline, highlighted by key submissions and approvals from the broadest pipeline in the industry in Injectable Aesthetics, the introduction of scientifically-differentiated products in Dermatological Skincare, and the initiation of clinical trials for new nemolizumab indications in Therapeutic Dermatology.
• Extended scientific leadership in dermatology, with a strong presence at key congresses and industry events as well as market leadership in education.
• Core EBITDA grew to 1,211 million USD, up 18.9% year-on-year at constant currency, ahead of net sales growth. Reported Core EBITDA margin was 23.3%, representing a year-on-year margin expansion of 24 basis points at constant currency, which exceeded initial expectations in a year of major launches and reinvestments in growth.
• Core EPS³ grew to 3.69 USD, up 76.7% year-on-year, driven by strong Core EBITDA growth, reduced financing and tax expenses, as well as share repurchases.
• Strengthened balance sheet and cash flow generation, with net leverage⁴ reduced to 1.5x at the end of December 2025, alongside lowered interest payments and improvements in net working capital.
• 2026 full-year guidance with attractive top- and bottom-line growth, expecting net sales growth of 17-20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency.
• Sustained confidence in the mid-term outlook, specifying 2023-2027 guidance within or above the previously communicated ranges and raising the peak sales guidance for Nemluvio from above 2 billion USD to above 4 billion USD for prurigo nodularis and atopic dermatitis globally.

“2025 was an outstanding year for Galderma and a defining step in our journey towards becoming the undisputed dermatology powerhouse. We delivered record financial results with broad-based net sales growth across all product categories and geographies, driven by clear strategic focus, disciplined execution, science-driven innovation and the successful scaling of our proven Integrated Dermatology Strategy. With a strengthened financial profile, global scale and the world’s broadest dermatology portfolio, we enter our next phase of growth with clarity, confidence and ambition.”

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

Commercial performance

For the full year 2025, Galderma delivered record net sales of 5,207 million USD, exceeding 5 billion USD for the first year. Year-on-year net sales growth for the year was 17.7% at constant currency. Growth overall was predominantly volume-driven, with a favorable product mix more than offsetting pricing effects from the competitive environment. In the fourth quarter, net sales grew 25.2% year-on-year at constant currency, reflecting an acceleration in each product category.

Net sales growth for the year was widespread across geographies and product categories. Both geographies’ net sales grew double-digits while all product categories outpaced their respective markets.

International sustained its strong net sales growth momentum in highly attractive, largely underpenetrated markets. Injectable Aesthetics delivered double-digit net sales growth and outperformed the market in both Neuromodulators and Fillers & Biostimulators. Both Restylane and Sculptra delivered net sales growth with market share gains in most key countries despite continued softness in the Filler market. Dermatological Skincare also delivered double-digit net sales growth, with outstanding growth particularly in India and China. Therapeutic Dermatology net sales growth was driven by Nemluvio, with strong launch trajectories also in its first European markets.

The U.S. delivered net sales growth in each product category. Net sales growth was especially strong for Neuromodulators as well as for Therapeutic Dermatology, driven by Nemluvio. Injectable Aesthetics outgrew a soft market and gained share in both Neuromodulators and Fillers & Biostimulators. Neuromodulators and Biostimulators net sales grew double-digit while Fillers continued to be impacted by market softness. Dermatological Skincare net sales growth was mainly driven by Alastin, growing double-digits, while Cetaphil had a strong fourth quarter from the ramp-up of recent launches and year-end activations. Therapeutic Dermatology had outstanding net sales growth driven by Nemluvio’s strong trajectory in prurigo nodularis and atopic dermatitis, more than offsetting the anticipated decline in mature products.

Overall, Galderma capitalized on its five key opportunity areas for 2025, including 1) significant launches, including the strong uptake of Nemluvio and Relfydess in first markets and of Sculptra in China, 2) market share gains, 3) a strengthened financial profile, 4) a shift to long-term growth, and 5) dynamic commercial investments to continue to drive growth.

Injectable Aesthetics

Injectable Aesthetics net sales for the full year were 2,572 million USD, up 11.5% year-on-year at constant currency. Galderma remained on a strong growth trajectory, consistently outpacing the market, driven by focused execution, new product launches and further geographic penetration.

Neuromodulators net sales were 1,471 million USD, up 14.3% year-on-year at constant currency. Both geographies delivered double-digit growth and continued to gain market share. Dysport^® continued to outperform globally, with strong growth in top markets. Relfydess had a strong year of launches, gaining significant share as a next generation neuromodulator recognized for its superior profile, while setting a high comparable base for 2026. Demonstrating focused execution of its Neuromodulator portfolio strategy, with net sales increasing for both Relfydess and Dysport in markets where Relfydess was launched.

Fillers & Biostimulators net sales were 1,101 million USD, up 8.0% year-on-year at constant currency. Both geographies continued to gain market share, driven especially by Sculptra and the uptake of new launches, including Sculptra in China and Restylane^® SHAYPE in Brazil. Fillers globally continued to be impacted by market softness with important pricing pressures, as a result of lower consumer demand and aggressive promotional activity from competitors in the mid-face. Biostimulators maintained its double-digit net sales growth momentum in both geographies, as Sculptra continued to strengthen its position as the leading brand with proven regenerative capabilities. Sculptra growth was particularly high in key International markets and especially in China thanks to a strong launch trajectory.

Galderma also made progress in preparing the next frontier of growth in Injectable Aesthetics, maintaining its commercial and regulatory momentum.

In Neuromodulators, Relfydess is quickly ramping up and is now approved in 23 International markets. On February 2, 2026, Galderma announced that the U.S. Food & Drug Administration (FDA) accepted the resubmission of Relfydess’ Biologics License Application (BLA) for the temporary improvement of moderate‑to‑severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults.

In Fillers, the U.S. FDA approved Restylane Lyft with Lidocaine in November 2025 for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion. In Biostimulators, Galderma continues to demonstrate leadership in regenerative aesthetics. Beyond the important launch of Sculptra in China, a new chapter opened for the brand in December 2025, with the European Union (EU) Medical Device Regulation (MDR) certification expanding its approved clinical applications beyond the face to include the gluteal area, posterior thighs, décolletage, and upper arms.

Galderma is also shaping the aesthetics journey for patients undergoing medication-driven weight loss, based on its proven Restylane and Sculptra portfolio. With its dedicated scientific agenda for market-leading education and training activities with healthcare professionals, Galderma also saw strong conversion of new patients to its portfolio in the U.S. from its SCULPT & LIFT direct-to-consumer campaign.

Dermatological Skincare

Dermatological Skincare net sales for the full year were 1,449 million USD, up 9.3% year-on-year at constant currency. Both Cetaphil and Alastin continued on their strong growth trajectories, outpacing their respective segments globally.

Growth was very strong in International markets, with Cetaphil gaining share and delivering exceptional performance in Asia. Notably, China and India continued to deliver outstanding net sales growth, with particularly strong performance from year-end activations. Alastin continued to ramp-up in International markets. In the U.S., growth was driven by Alastin, which continued to deliver double-digit growth and to be the fastest growing top physician-dispensed skincare brand. Cetaphil in the U.S., in a year of constrained consumer spending, had a strong fourth quarter from the ramp-up of recent launches and year-end activations.

Galderma’s digital-first strategy remained a powerful growth engine for Cetaphil, with e-commerce its fastest growing channel. Growth was particularly strong in the fourth quarter for Cetaphil in China, with strong year-end activations. This included another record performance during the Double 11 shopping festival, outperforming the skincare market online, a major Zootopia 2 campaign, and celebrity endorsements. Globally, Cetaphil also had over 100 million impressions from key global activations, including CetaSphere – one of the world’s largest skincare advocacy networks – and Derm on Tour – an immersive, science-driven pop-up experience offering free dermatology consultations in select cities. Alastin grew across channels, with a focus on physician-first engagement.

Galderma also launched differentiated innovation in Dermatological Skincare to drive further growth, starting in the U.S. with the opportunity to expand in International markets. Among key Cetaphil launches were the Skin Activator Hydrating & Firming line for aging, fragile skin and the Nourishing Oil to Foam Cleanser for sensitive skin, both creating entirely new categories based on strong science delivering breakthrough benefits. Alastin^® also further strengthened its portfolio with the launch of Restorative Skin Complex featuring Next Generation TriHex Technology (TriHex+^TM). This formula includes two groundbreaking additions, proven to help visibly restore facial radiance and plumping by supporting the skin’s own regenerative abilities. In International markets, Galderma continued to roll-out key innovation, such as Cetaphil’s Bright Healthy Radiance or Gentle Exfoliating lines.

Therapeutic Dermatology

Therapeutic Dermatology net sales were 1,185 million USD, up 50.2% year-on-year at constant currency. Net sales growth was very strong, driven by an outstanding launch trajectory of Nemluvio in prurigo nodularis and atopic dermatitis. This more than offset the anticipated decline in the mature Therapeutic Dermatology portfolio in the U.S., along with modest growth from the mature portfolio in International markets.

For the year, Nemluvio contributed 452 million USD in net sales. The vast majority of Nemluvio sales were recorded in the U.S., split roughly equally between prurigo nodularis and atopic dermatitis, with the share of the latter increasing quickly. The launch trajectory has been very strong in the U.S., and even stronger in Nemluvio’s first International launch markets despite representing a small share of sales.

Nemluvio’s significant market share gains in the U.S. are underpinned by a differentiated profile, salesforce expansion, market-leading education, and enhanced market access. In the U.S., Nemluvio paid new patient starts (NBRx), from the end of December 2025 to the end of January 2026, was trending at about 35% market share in prurigo nodularis and about 8% in atopic dermatitis. The majority of patients starting treatment continue to be new to biologics. Following broad first-line biologic access for Nemluvio across commercial plans in 2025, Galderma secured its first major Medicare access win beginning January 2026. An important gross-to-net impact is expected in the first quarter of the year, driven both by access expansion and typical seasonal copay resets in the period.

Beyond launching Nemluvio in five International markets in 2025, Galderma continued to make regulatory progress, with approvals now secured in Canada and South Korea, and additional submissions underway.

Scientific leadership and excellence in medical education

In 2025, Galderma reaffirmed its leadership in dermatology, supported by an innovative, science‑based portfolio, continued progress on its scientific agenda, and a strong presence at scientific congresses and key industry events.

Among the highlights, Galderma presented long‑term Nemluvio data in prurigo nodularis and atopic dermatitis, reinforcing its consistent safety profile and durable clinical efficacy across both indications up to two years, at the European Academy of Dermatology and Venereology (EADV) 2025, the Revolutionizing Atopic Dermatitis (RAD) Conference, and the XIV International Congress of Dermatology (ICD). In addition, Galderma announced the initiation of two new clinical trials evaluating nemolizumab in Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO), with the first patient enrolled in the CPUO trial in December 2025.

As well as presenting new Relfydess data throughout the year, Galderma unveiled final nine-month data from a phase IV first-of-its-kind trial showing lasting efficacy and patient satisfaction with Restylane Lyft or Contour^® in combination with Sculptra when addressing facial aesthetic changes following medication-driven weight loss. This work supported the development of international consensus‑based guidelines.

Galderma also had a strong presence at additional major medical congresses, including the IMCAS World Congress 2025, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Monaco, AMWC Dubai, and the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting.

During the year, over 290,000 healthcare professionals were reached through education, training and medical awareness activities,⁵ including the Galderma Aesthetic Injector Network (GAIN) – which celebrated its 10^th anniversary in 2025 – the Global Sensitive Skincare Faculty (GSSF), and the Skin Knowledge and Innovation Network (SKIN).

Financial scorecard

For the full year 2025, Galderma delivered 1,211 million USD in Core EBITDA, up 18.9% year-on-year at constant currency. The reported Core EBITDA margin was 23.3%, representing a margin expansion of 24 basis points at constant currency compared to 2024. Core EBITDA grew ahead of net sales, in a year of major launches with reinvestments into growth, thanks to ongoing operating leverage as well as a reduced adverse P&L impact from nemolizumab as a result of greater sales. Improvements in operating expenses also offset the impact of pricing effects and unfavorable product mix on gross margin.

Galderma delivered even greater growth in Core net income for the full year. Core net income was 871 million USD, up 75.4% year-on-year, driven by strong Core EBITDA growth as well as reduced financing and tax expenses. The latter include a one-time, non-cash benefit on the effective tax rate, from recognizing deferred tax assets on past tax losses in Switzerland.

Galderma demonstrated very strong cash generation for the year, due to significant Core EBITDA growth, favorable net working capital movements, and lower interest payments. Net working capital positions improved significantly behind effective net working capital management, structural improvements driven by shifts in market and product mix and phasing benefits.

Core CapEx benefitted from improved phasing of project spend as well as continued focus on spend efficiencies and site operating performance. Core CapEx as a percentage of sales continues to come down due to the high net sales growth. Investments significantly increased capacity at all of Galderma’s manufacturing sites, including the build-out of the biologics production site for Relfydess in Uppsala, Sweden. Beyond CapEx, Galderma also committed to spend more than 650 million USD on U.S. manufacturing through 2030, via contract manufacturing partners. Additional technology transfers to the U.S. focused on key growth drivers have also been initiated.

Core EPS was 3.69 USD per share, up 76.7% year-on-year, benefitting from the share repurchases executed in the year. Galderma repurchased shares for 363 million USD in the accelerated bookbuild offerings of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) which took place throughout the year. Funded from existing liquidity on hand, they are to be held in treasury to support Galderma’s employee participation plans, business development activities and/or treasury management.

Continuing on a rapid deleveraging trajectory, net leverage came down to 1.5x at the end of December 2025. For the full year, Galderma’s ambitious deleveraging and refinancing was underpinned by further partial repayment of its Term Loan of 1.5 billion USD. This was based on an early debt repayment of 240 million USD and debt refinancing of 1,260 million USD, which included several CHF and EUR bond issuances.

Building on its strengthened financial profile headlined by investment grade ratings from S&P (BBB, positive) and Fitch (BBB, stable), Galderma swiftly replaced in February 2026 its Revolving Credit Facility originally implemented at the time of the IPO in 2024, with significantly improved terms and a size increase from 0.7 to 1 billion USD.

Galderma continued to demonstrate its commitment to superior shareholder returns, including through share repurchases and dividend payment. Following another record year, Galderma’s Board will propose, for approval at the upcoming Annual General Meeting, a dividend payment out of reserves from capital contributions of 0.35 CHF (gross) per share.⁶

Galderma continued to diversify and strengthen its long‑term shareholder base. This included an additional 10% equity investment from L’Oréal, bringing their total shareholding in Galderma to 20%, with the transaction closed in February 2026.

ESG remains an integral pillar of Galderma’s strategy. In 2025, Galderma focused on strengthening the three constitutive elements of its ESG Strategy. This included streamlining its ESG Framework through an inaugural double materiality assessment, strengthening its ESG Governance to support auditable non-financial reporting, and delivering against a clear ESG Ambition. Galderma’s ESG Strategy has gained external recognition through improvements in key ESG ratings. For instance, in 2025, Galderma received an AA rating (on a scale of AAA-CCC) in the MSCI ESG Ratings assessment, up from BBB in 2024.

Outlook

Galderma expects 2026 to be another year of opportunities, with very strong top-line growth and significant Core EBITDA margin expansion. Galderma expects net sales growth of 17-20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency for the full year.

Galderma’s proven integrated dermatology strategy is underpinning net sales growth, expected to be ahead of the market in each product category. It also continues to drive operating leverage, while allocating appropriate level of investments into growth in a competitive environment. Confident in the ability to deliver, the guidance also reflects existing uncertainties. Galderma’s dynamic approach to commercial investments provides resilience and flexibility to capture opportunities, leveraging a broad portfolio and geographic reach.

In terms of foreign exchange impacts, while guidance is at constant currency, based on spot rates as of the end of February 2026, USD depreciation is expected to have a positive impact on reported net sales and a negative impact on reported Core EBITDA margin, which is due to headquarter costs denominated mainly in CHF. A table with Galderma’s exposure to key foreign exchange currency pairs is available in the Appendix. As for tariffs, exposure remains manageable, with the guidance assuming a 15% U.S. tariff on the import value of Restylane and Sculptra.

Following a stronger than originally anticipated first year on the market in the U.S. and in European markets in prurigo nodularis and atopic dermatitis, Galderma is raising its peak sales guidance for Nemluvio from above 2 billion USD to above 4 billion USD for both indications globally. This reflects its strong launch trajectory with higher demand than expected based on positive real-world experience in addition to an already differentiated clinical profile.

In light of its greater expectation for Nemluvio and confidence in its broad-based growth trajectory, Galderma is specifying its 2023-2027 mid-term guidance to be within or above the previously stated ranges as per the table available in the Appendix, along with additional modelling metrics for 2026. Guidance for the mid-term is based on the same tariff assumption as for 2026⁷, and subject to the same expected impact from foreign exchange.

Webcast details

Galderma will host its financial results call today at 14:00 CET to discuss the full year 2025 results and respond to questions from financial analysts. Investors and the public may access the webcast by registering on the Galderma Investor Relations website at https://investors.galderma.com/events-presentations.

2025 Annual Report

Galderma issued its 2025 Annual Report today, and it is available at https://investors.galderma.com/financial-reports.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Appendices

Appendix 1: Full year 2025 net sales by product category and geography

Appendix 2: Q4 2025 net sales by product category and geography

Appendix 3: Reconciliation of FY 2025 P&L from IFRS to Core reporting

Appendix 4: Reconciliation of FY 2025 of Core EBITDA to IFRS Net Income

Appendix 5: Reconciliation of FY 2025 from IFRS Net Income to Core Net Income

Appendix 6: FY 2025 Total Net Indebtedness

Appendix 7: Additional modelling metrics

Appendix 8: Mid-term guidance, based on assumed tariffs⁷ & all at constant currency (CC)

Appendix 9: Overview of foreign exchange rate exposure

Notes and references

1. Constant currency (CC) year-on-year growth is defined as the annual growth rate of net sales excluding the impact of exchange rates movements and excluding hyperinflation economies. The impact of changes in foreign exchange rates are excluded by translating all reported revenues during the two periods at average exchange rates in effect during the previous year.
2. Core EBITDA is defined as EBITDA excluding the following items that are deemed non-core: acquisition and disposal; integration and carve-out related income and expenses; onerous contracts; business disposal gains and losses; restructuring and reorganization related items; litigation related items; impairment of PPE and intangible assets; IPO-related incentive plans as well as other income and expense items that management deems exceptional and that are expected to accumulate within the year to be over 2 M USD threshold (2024: 1 M USD threshold). These include transformation, carve-out and build-up related project costs as well as post-acquisition related accounting impacts.
3. Core EPS is calculated as Core net income divided by the weighted average number of outstanding shares.
4. Leverage is defined as Total Net Indebtedness divided by Core EBITDA on a twelve-months rolling basis.
5. Single training contact points, one healthcare professional can be trained more than once.
6. Dividend-bearing shares are all shares issued except for treasury shares held by Galderma Group AG or its direct or indirect fully owned subsidiaries as of the record date. The dividend will be paid in CHF. The distribution of 0.35 CHF per share is subject to the overall cap of 135 million USD converted into CHF two business days prior to the Annual General Meeting divided by the number of outstanding shares. Provided that the proposed dividend payment out of reserves from capital contributions is approved, the payment will be made as of April 28, 2026 to holders of shares on the record date April 27, 2026. The shares will be traded ex-dividend as of April 24, 2026 and, accordingly, the last day on which the shares may be traded with entitlement to receive the dividend will be April 23, 2026.
7. Assumes a 15% U.S. tariff on the import value of Restylane and Sculptra.
8. 2024 adjustments include 48 M USD for IPO related incentive plans, 4 M USD for VCB bonus, 12 M USD litigation, 9 M USD restructuring, 8 M USD for platform transformation costs, 6 M USD for IPO, 4 M USD for operating FX. 2025 adjustments include 18 M USD impairment, 13 M USD restructuring, 12 M USD litigation, 7 M onerous items, 2 M USD M&A, 19 M USD for operating FX; offset by income of 12M from pension accounting and 2M impairment reversal.
9. Value Creation Bonus (VCB): Non-cash item, settled and discontinued at IPO: pre-IPO long-term incentive (LTI) plan open to selected management employees. Post IPO: VCB has been replaced by LTI plan, which was included in Galderma’s 2025 and mid-term Core EBITDA margin guidance.
10. Core Net Income is defined as net income adjusted for the same items that are treated as exceptional for purposes of defining Core EBITDA, as well as amortization of intangible assets and foreign exchange gains and losses on financing activities. Taxes on the adjustments between IFRS net income and Core Net Income take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact.
11. Indebtedness includes financial debt and lease liabilities.
12. Includes assumptions for other income and expenses related to tangible asset impairments, ongoing litigation and onerous items, restructuring charges and others, excluding M&A fees and the impact from Operating Fx.
13. On reported profit before tax.
14. Includes interest income and interest expense, excluding Fx impact.
15. Includes a one-time, non-cash benefit from recognizing deferred tax assets on past tax losses.
16. ‘Teens’ defined as numbers greater than 10% and lower than 20%.
17. Factors in the simulation of all foreign exchange rate exposures, including for currencies not listed in the table of exchange rates for significant FX exposures.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260304261230/en/

Contacts

For further information:

Media

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Investors

Emil Ivanov

Head of Strategy, Investor Relations and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43